Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

被引：0

作者：

Fang, W. F. ^{[1
]}

Bu, Q. ^{[2
]}

Wang, Q. M. ^{[3
]}

Zhao, W. H. ^{[4
]}

Wang, L. P. ^{[5
]}

Dong, X. R. ^{[6
]}

Chen, P. F. ^{[7
]}

Wen, Z. B. ^{[8
]}

Jia, J. ^{[9
]}

Jiang, G. M. ^{[9
]}

Zhang, L. ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China

[3] Henan Canc Hosp, Zhengzhou, Peoples R China

[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China

[5] Baotou Canc Hosp, Baotou, Peoples R China

[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[7] Zhuji Peoples Hosp, Zhuji, Peoples R China

[8] Peoples Hosp Gaozhou, Gaozhou, Peoples R China

[9] Dongguan Peoples Hosp, Dongguan, Peoples R China

来源：

关键词：

aumolertinib; high-dose; uncommon EGFR mutations;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.09-07

引用

页码：S333 / S334

页数：2